Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Trail Making Test× | Addenbrooke's kognitiivne hindamine× | |
|---|---|---|
| Valdkond | Neuropsühholoogia | Neuropsühholoogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1958 | 2000 |
| Looja≠ | Ralph Reitan | Padasalai Mathuranath |
| Tüüp≠ | Clinician-administered neuropsychological test of attention and executive function | Clinician-administered comprehensive cognitive examination |
| Algallikas≠ | Reitan, R. M. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8(3), 271-276. DOI ↗ | Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11), 1613-1620. DOI ↗ |
| Rööpnimetused≠ | TMT, Trails A, Trails B, Trail Making A | ACE, ACE-R, ACE-III, Addenbrooke Cognitive Examination |
| Seotud | 5 | 5 |
| Kokkuvõte≠ | The Trail Making Test (TMT) is a simple, brief neuropsychological test developed by Reitan in 1958 that measures visuomotor processing speed, attention, and executive function. The TMT comprises two forms: Part A, which assesses basic processing speed and visual scanning, and Part B, which assesses executive function, task-switching, and cognitive flexibility. Despite its simplicity, the TMT is highly sensitive to cognitive impairment across a wide range of neurological and psychiatric conditions and remains one of the most widely used screening tests in neuropsychology. | The Addenbrooke's Cognitive Examination (ACE) is a brief yet comprehensive clinician-administered cognitive battery designed to assess multiple cognitive domains and differentiate between types of dementia. Originally developed by Mathuranath and colleagues at Cambridge University in 2000, the ACE was created to address limitations of single-domain screening tools. The revised version (ACE-R, 2006) and further refined version (ACE-III, 2013) provide updated norms and improved sensitivity. The ACE-R and ACE-III are particularly valuable for distinguishing Alzheimer's disease from frontotemporal dementia. |
| ScholarGateAndmestik ↗ |
|
|